N/A N=104 Behavioral Economics and Adherence in Teens (BEAT!)
Epilepsy · Adherence, Medication
Primary: Electronically Monitored Adherence — 45.5; 50.5 units on a scale — p=0.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=76 Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Stage I Multiple Myeloma · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: Percentage of Patients Achieving sCR — 76 percentage of participants
Phase 2 N=192 Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty
Hip Arthropathy
Primary: Daily Opioid Consumption — 29.3; 30.8; 49.6; 51.8 milligram — p=0.69
Phase 1 N=30 Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Recurrent Lymphoma · Recurrent Malignant Solid Neoplasm · Recurrent Primary Central Nervous System Neoplasm
Primary: MTD/RP2D of Pevonedistat in Combination With Irinotecan and Temozolomide — 35 mg/m^2
N/A N=50 Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial
Schizophrenia · Schizoaffective Disorder · Brief Psychotic Disorder
Primary: Difference in Participant's Total Distance During 6-minute Walk — 458.775; 467.209; 452.355; 448.711 meters
Phase 3 N=683 Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B — -17.48; -19.20; -19.94; -20.78 units on a scale — p=0.0937
Phase 2 N=89 An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
Malignant Pleural Mesothelioma
Primary: Number of Participants With Progression Free Survival (PFS) Responders and Non-responders at Month 6 — 26; 51 Participants
Phase 3 N=106 Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
Primary: Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 — 17; 14 Participants
N/A N=52 Neuromodulation to Treat Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Normal Ejection Fraction
Primary: E/e' (Early Mitral Inflow Doppler Velocity to the Early Diastolic Mitral Annulus Velocity) — 10.4; 9.9 ratio
Phase 2 N=28 Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Advanced Bile Duct Carcinoma · Advanced Gallbladder Carcinoma · Refractory Bile Duct Carcinoma
Primary: Progression-free Survival (PFS) — 37.0 percentage of participants
Phase 2 N=45 Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
Coronavirus Infection · Covid-19 · SARS-CoV-2
Primary: Proportion of Patients With Recovery — 29; 15 Participants — p=1
Phase 4 N=528 CeraVe Diabetes Mellitus
Diabetes Complications
Primary: Percentage of Participants Reporting Adverse Events (AE) — 0 percentage of participants
N/A N=40 Characterization of AmnioExcel Plus in Two Treatment Paradigms
Diabetic Foot Ulcer
Primary: Number of Participants Who Healed — 6; 10 Participants
N/A N=10 Implantation of the Cochlear® Nucleus® System in Adults With Single-Sided Deafness
Single Sided Deafness
Primary: Number of Subjects With Adverse Events — 1 participants
N/A N=27 Integrated Treatment for Posttraumatic Stress Disorder and Substance Abuse in Young Adults
Substance Use Disorder · Posttraumatic Stress Disorder
Primary: Change in Severity of Posttraumatic Stress Disorder Symptoms as Measured by the National Stressful Events PTSD Scale — 1.92; 2.61 score on a scale — p=.041